Steven Orlov BSc,
David Orlov HBSc, Michael Shaytzag HBSc,
Mark Dowar HBSc,
Vafa Tabatabaie MD,
Philip Dwek HBSc,
Jonathan Yip HBSc,
Cindy Hu BSc,
FRCSC Jeremy L. Freeman MD,
FRCPC Paul G. Walfish MD,
Steven Orlov,
David Orlov,
Michael Shaytzag,
Mark Dowar,
Vafa Tabatabaie,
Philip Dwek,
Jonathan Yip,
Cindy Hu,
Jeremy L. Freeman,
Paul G. Walfish
[show abstract]
[hide abstract]
ABSTRACT: Background.Though age and primary tumor size predict cancer-specific survival in well-differentiated thyroid carcinoma (WDTC), their influence on residual/recurrent disease has not been elucidated.Methods.In a retrospective study, residual/recurrent disease was defined by the surrogate outcome of positive (≥2 μg/L) follow-up stimulated thyroglobulin after surgery and radioactive remnant ablation. Age, primary tumor size, and clinical staging systems were examined in the context of stimulated thyroglobulin outcome.Results.A total of 246 patients were followed up for a mean of 5.8 years. No significant difference in age (t(239) = 0.61, p > .05) or tumor size (t(237) = 0.16, p > .05) was found among patients with positive follow-up stimulated thyroglobulin compared with those with negative results. pTNM staging failed to demonstrate significant, stage-dependent increase in the percentage of patients with positive stimulated thyroglobulin, χ2(2, N = 229) = 0.17, p > .05, unlike staging based solely on surgical pathology, χ2(2, N = 241) = 34.97, p < .001.Conclusion.Age, primary tumor size, and pTNM staging do not predict risk for residual/recurrent WDTC, whereas extrathyroidal extension at initial surgery is predictive. © 2009 Wiley Periodicals, Inc. Head Neck, 2009
Head & Neck 05/2009; 31(6):782 - 788. · 2.40 Impact Factor
